Talis Biomedical Corporation

As of June 30, 2024, Talis Biomedical Corporation has 1.82M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 52.57, and the price-to-book ratio stands at -0.03.

As of June 30, 2024, Talis Biomedical Corporation maintains a current ratio of 7.76, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -52.13, reflecting losses generated across the asset base.

As of the close on March 30, 2026, Talis Biomedical Corporation's stock has gained approximately 63.22% over the past 52 weeks. The 50-day moving average sits at 2.84, while the 200-day moving average is 1.97.

Over the twelve months ended June 30, 2024, Talis Biomedical Corporation posted a gross margin of 93.33, reflecting its pricing power and cost economics. The operating margin of -18,374.00 and net profit margin of -17,008.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield is negative at -255.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.01, meaning Talis Biomedical Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Talis Biomedical Corporation's most recent stock split took place on July 6, 2023 with a 15:1 split ratio.

As of June 30, 2024, Talis Biomedical Corporation has an Altman Z-Score of -12.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.